Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Laura Clague Sells 825 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) CFO Laura Clague sold 825 shares of the stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $21.51, for a total transaction of $17,745.75. Following the completion of the transaction, the chief financial officer now directly owns 37,030 shares in the company, valued at approximately $796,515.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Travere Therapeutics stock opened at $21.44 on Friday. Travere Therapeutics, Inc. has a 52-week low of $12.75 and a 52-week high of $31.65. The company has a fifty day moving average of $26.16 and a 200-day moving average of $27.57. The company has a quick ratio of 5.23, a current ratio of 5.28 and a debt-to-equity ratio of 1.80.

Travere Therapeutics (NASDAQ:TVTX – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.35). Travere Therapeutics had a negative net margin of 88.46% and a negative return on equity of 70.33%. The business had revenue of $48.49 million during the quarter, compared to analysts’ expectations of $51.92 million. During the same period last year, the company posted ($0.96) EPS. Travere Therapeutics’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts predict that Travere Therapeutics, Inc. will post -3.58 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. Piper Sandler decreased their price target on shares of Travere Therapeutics from $42.00 to $40.00 in a report on Friday, May 6th. HC Wainwright assumed coverage on shares of Travere Therapeutics in a report on Monday, February 28th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Zacks Investment Research raised shares of Travere Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 28th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $33.38.

Several institutional investors have recently made changes to their positions in the company. MetLife Investment Management LLC boosted its stake in shares of Travere Therapeutics by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 33,799 shares of the company’s stock valued at $871,000 after purchasing an additional 12,475 shares in the last quarter. Monashee Investment Management LLC purchased a new stake in Travere Therapeutics during the 1st quarter valued at $2,577,000. E Fund Management Co. Ltd. purchased a new stake in Travere Therapeutics during the 1st quarter valued at $205,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Travere Therapeutics by 2.3% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 235,774 shares of the company’s stock valued at $6,076,000 after buying an additional 5,405 shares during the period. Finally, Blueshift Asset Management LLC purchased a new stake in Travere Therapeutics during the 1st quarter valued at $556,000.

Travere Therapeutics Company Profile (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Featured Stories